01. Why look beyond body weight?
RETROD is our name for retatrutide research material. The research story reaches beyond a number on the scale: investigators have measured fat inside the liver, blood glucose, body composition, appetite, knee pain and physical function.
This guide brings those results together by outcome, with the study population and measurement period beside the numbers. The amounts shown in tables identify trial groups, not recommended personal doses. Clinical findings describe the study formulations; they are not test results for an MGMT vial.
02. Three receptors, one research molecule
Retatrutide activates GIP, GLP-1 and glucagon receptors. This combination joins pathways involved in appetite and glucose regulation with glucagon-related energy metabolism. In preclinical experiments, glucagon-receptor activity contributed to increased energy expenditure alongside reduced food intake. [1]
That mechanism helps explain the interest in outcomes beyond weight loss. It does not mean that a sensation of warmth proves increased metabolism, or that an animal energy-expenditure result provides a quantified human effect.
An early human pharmacokinetic study reported a half-life of approximately six days, supporting investigation of once-weekly administration. [2]
03. Liver fat: dose-group results and missing data
The phase 2a MASLD substudy included 98 participants with at least 10% liver fat at baseline. MRI-PDFF measured the following changes. [3]
| Study group | Week 24 | Week 48 | Liver fat below 5% at week 24 |
|---|---|---|---|
| Placebo | +0.3% | −4.6% | 0% |
| 1 mg | −42.9% | −51.3% | 27% |
| 4 mg | −57.0% | −59.0% | 52% |
| 8 mg | −81.4% | −81.7% | 79% |
| 12 mg | −82.4% | −86.0% | 86% |
These are relative liver-fat changes, not total weight loss or proof of fibrosis reversal. MRI data were available for 78.6% of participants at week 24 and 43.9% at week 48; missing later measurements limit interpretation. [3]
04. Liver biomarkers, triglycerides and ketones
Triglycerides improved versus placebo at ≥4 mg. K-18 and Pro-C3 decreased in selected groups; ALT, AST, FIB-4 and ELF showed no consistent improvement. [3]
β-hydroxybutyrate increased at week 24 in groups receiving 4 mg or more. This time-specific finding does not establish a sustained effect or quantify an individual’s metabolic rate. [3]
05. Body composition: fat mass and lean mass
A DXA substudy enrolled 189 adults with type 2 diabetes. Its primary assessment was change in total fat mass at 36 weeks. Only 103 participants completed treatment with both baseline and week-36 scans, so the later measurements do not represent every enrolled participant. [4]
| Study group | Fat-mass reduction |
|---|---|
| Retatrutide 0.5 mg | 4.9% |
| Retatrutide 4 mg, pooled | 15.2% |
| Retatrutide 8 mg, pooled | 26.1% |
| Retatrutide 12 mg | 23.2% |
| Dulaglutide 1.5 mg | 2.6% |
| Placebo | 4.5% |
Lean mass also decreased. The authors found that its contribution to overall weight loss was similar to that seen with other obesity treatments. These results support substantial fat loss, not a promise of muscle preservation or muscle gain.
DXA separates tissue compartments more usefully than a bathroom scale alone. “Lean mass” includes more than skeletal muscle, so it should not be treated as a direct measure of strength.
06. Blood glucose: phase 2 and phase 3 findings
In the phase 2 type 2 diabetes trial, HbA1c changes at week 24 differed by dose and escalation group. Values below are percentage-point reductions, not relative percentages. [5]
| Study group | HbA1c reduction |
|---|---|
| Retatrutide 0.5 mg | 0.43 points |
| Retatrutide 4 mg, with escalation | 1.39 points |
| Retatrutide 4 mg, without escalation | 1.30 points |
| Retatrutide 8 mg, slower escalation | 1.99 points |
| Retatrutide 8 mg, faster escalation | 1.88 points |
| Retatrutide 12 mg, with escalation | 2.02 points |
| Dulaglutide 1.5 mg | 1.41 points |
| Placebo | 0.01 points |
The peer-reviewed TRANSCEND-T2D-1 trial included 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone. Mean starting HbA1c was 7.9%. The following 40-week figures use the published treatment-regimen estimand. [6]
| Group | HbA1c reduction | Body-weight reduction |
|---|---|---|
| 4 mg | 1.69 points | 11.5% |
| 9 mg | 1.86 points | 13.9% |
| 12 mg | 1.94 points | 15.3% |
| Placebo | 0.81 points | 2.6% |
Results in a diabetes population answer a different question from results in an obesity trial without diabetes. Neither table establishes diabetes remission or justifies changing prescribed treatment.
07. Knee pain and easier movement
TRIUMPH-4 studied 445 adults with obesity or overweight and knee osteoarthritis over 68 weeks. Lilly reported the following efficacy-estimand results. [7]
| Outcome | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Body-weight reduction | 26.4% | 28.7% | 2.1% |
| WOMAC pain improvement | 4.5 points | 4.4 points | 2.4 points |
| WOMAC function improvement | 4.1 points | 4.2 points | 2.1 points |
Average baseline pain was 6.0. These results concern knee osteoarthritis, not demonstrated relief of back pain or repair of cartilage. The illustration above represents a positive conversation, not a clinical outcome.
08. Cardiometabolic markers and the wider research programme
Cardiometabolic markers and clinical outcomes answer different questions. Changes in glucose, weight or blood pressure do not alone establish fewer heart attacks, strokes or kidney-failure events. [6]
The published 80-week TRIUMPH-1 trial reported knee-pain outcomes in 574 participants with knee osteoarthritis and sleep-apnoea outcomes in 243 participants with obstructive sleep apnoea. Results concern those defined subgroups and the stated analysis methods. [10]
A separate 80-week phase 3 trial, TRIUMPH-2, studied 1,152 adults with overweight or obesity and type 2 diabetes. It adds evidence in that population; it is not a head-to-head comparison with the trials above. [11]
09. Appetite, hunger and “food noise”
There is retatrutide-specific research on eating behaviour. An exploratory analysis of 275 adults with type 2 diabetes assessed appetite questionnaires at 24 and 36 weeks. [8]
At week 24, groups receiving at least 4 mg reported greater reductions in appetite, hunger and anticipated food consumption than placebo. The 8 mg and 12 mg groups also showed improvements in perceived hunger and tendency to overeat at both assessments. Greater dietary restraint versus placebo was seen with 12 mg at week 36.
Changes in these measures correlated with weight reduction. “Food noise” is an informal phrase; the study used defined questionnaires rather than that single label. It does not establish that retatrutide treats alcohol dependence, compulsive behaviour or every kind of craving.
10. The weight-loss context and why time matters
The phase 2 obesity trial enrolled 338 adults. Its mean body-weight reductions provide context for the other outcomes in this guide. [9]
| Group | Week 24 | Week 48 |
|---|---|---|
| 1 mg | 7.2% | 8.7% |
| 4 mg | 12.9% | 17.1% |
| 8 mg | 17.3% | 22.8% |
| 12 mg | 17.5% | 24.2% |
| Placebo | 1.6% | 2.1% |
These are group averages assessed over months. A trial’s highest dose is not automatically the right dose for an individual. Comparing results across different trials also requires attention to participants, duration, treatment adherence and analysis methods.
For longer observation periods, read Retatrutide long-term research. The phase 2 timeline focuses specifically on 24- and 48-week weight results.
11. Tolerability: the actual reported percentages
TRIUMPH-4 reported these adverse-event rates. “Dysesthesia” means altered or unpleasant skin sensation. [7]
| Event | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Nausea | 38.1% | 43.2% | 10.7% |
| Diarrhoea | 34.7% | 33.1% | 13.4% |
| Constipation | 21.8% | 25.0% | 8.7% |
| Vomiting | 20.4% | 20.9% | 0% |
| Decreased appetite | 19.0% | 18.2% | 9.4% |
| Dysesthesia | 8.8% | 20.9% | 0.7% |
| Discontinued because of adverse events | 12.2% | 18.2% | 4.0% |
In the phase 2 obesity trial, gastrointestinal events were generally mild to moderate and dose-related. A lower starting dose reduced their frequency; dose-related heart-rate increases peaked at week 24 and subsequently declined. [9]
These tables are not a complete safety profile. A reported side effect should not be treated as evidence that a product is working or that a vial has the expected identity or purity.
12. Reading results, labels and batch reports
Keep three kinds of information separate: the molecule’s clinical evidence, a research product’s labelled quantity, and the analytical findings for a specific batch. A 20 mg vial label describes the vial’s contents; it does not mean a 20 mg dose.
A COA provides the results of the tests listed on that report. It does not transfer a clinical trial’s results to a commercial vial or establish suitability for human use. Review the matching lot on COA & Batch Reports, including whether its report is available or pending.
For storage and laboratory handling, follow the product-specific documentation. For personal symptoms, medication changes or health monitoring, work with a qualified clinician.
13. Questions that come up often
Does less liver fat mean liver disease is cured?
No. Fat content, inflammation and fibrosis are different endpoints. An imaging result alone does not answer every liver-health question.
Does losing weight mean all the loss is fat?
No. Body composition measures help distinguish fat and lean tissue. The DXA study above reported changes in both.
Do warmer skin or more energy prove increased fat burning?
No. Subjective feelings cannot quantify energy expenditure or verify a product.
Can retatrutide be ranked against other compounds using separate trial percentages?
Separate trials provide context, but a numerical ranking is not a controlled head-to-head comparison. Study design and population matter.
Are these customer results?
No. This page contains study findings and research explanations, not customer stories or testimonials.
14. Research terms, in plain language
| Term | Meaning |
|---|---|
| MASLD | Metabolic dysfunction-associated steatotic liver disease. |
| MRI-PDFF | An MRI measurement used to estimate liver fat fraction. |
| K-18 | Cytokeratin-18, studied as a marker of liver-cell injury. |
| Pro-C3 | A marker associated with collagen formation. |
| β-hydroxybutyrate | A ketone body relevant to fatty-acid metabolism. |
| DXA | A scan used to estimate fat, lean tissue and bone compartments. |
| HbA1c | A blood marker reflecting longer-term glucose exposure. |
| WOMAC | A questionnaire assessing osteoarthritis symptoms and function. |
| Non-HDL cholesterol | Total cholesterol minus HDL cholesterol. |
| Efficacy estimand | A defined analysis estimating effects under specified treatment-adherence conditions. |
| Percentage point | The absolute difference between two percentages. |
| Placebo | A comparison treatment without the active study drug. |
15. Sources and further reading
- Peer-reviewed studyCoskun et al. Retatrutide discovery and preclinical receptor studies. Cell Metabolism, 2022.
- Peer-reviewed studyUrva et al. Phase 1b retatrutide study in type 2 diabetes. The Lancet, 2022.
- Peer-reviewed studyRetatrutide for MASLD: randomized phase 2a trial. Nature Medicine, 2024.
- Peer-reviewed studyCoskun et al. Body-composition substudy in type 2 diabetes. Lancet Diabetes & Endocrinology, 2025.
- Peer-reviewed studyRosenstock et al. Phase 2 trial in type 2 diabetes. The Lancet, 2023.
- Peer-reviewed studyBajaj et al. TRANSCEND-T2D-1 phase 3 trial. The Lancet, 2026. DOI: 10.1016/S0140-6736(26)00967-0.
- Sponsor reportLilly. TRIUMPH-4 obesity and knee-osteoarthritis results, December 2025. Sponsor report.
- Peer-reviewed studyKanu et al. Appetite and eating behaviours during retatrutide treatment. Diabetes, Obesity and Metabolism, 2025.
- Peer-reviewed studyJastreboff et al. Phase 2 obesity trial. New England Journal of Medicine, 2023.
- Peer-reviewed studyJastreboff et al. TRIUMPH-1 obesity trial. New England Journal of Medicine, 2026. DOI: 10.1056/NEJMoa2604169.
- Peer-reviewed studyBellido et al. TRIUMPH-2: obesity and type 2 diabetes, 80-week phase 3 trial. The Lancet, 2026.
Retatrutide long-term research →
↑ Back to top